
Paul D Griffiths

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2068249/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protection offered by SARS coronavirus 2 vaccines against disease and infection. Reviews in Medical Virology, 2022, 32, e2303.	3.9	0
2	Experiences of pregnant women and healthcare professionals of participating in a digital antenatal CMV education intervention. Midwifery, 2022, 106, 103249.	1.0	8
3	Are the Patterns of Cytomegalovirus Viral Load Seen After Solid Organ Transplantation Affected by Circadian Rhythm?. Journal of Infectious Diseases, 2022, 226, 357-365.	1.9	2
4	Diagnostic accuracy of Abbott Architect Assay as a screening tool for human Tâ€cell leukaemia virus typeâ€1 and typeâ€2 infection in a London teaching hospital with a large solid organ transplant centre. Transfusion Medicine, 2022, 32, 256-260.	0.5	3
5	Playing chess with human cytomegalovirus. Reviews in Medical Virology, 2021, 31, 1-2.	3.9	0
6	Pathogenesis of human cytomegalovirus in the immunocompromised host. Nature Reviews Microbiology, 2021, 19, 759-773.	13.6	243
7	Changing knowledge, attitudes and behaviours towards cytomegalovirus in pregnancy through film-based antenatal education: a feasibility randomised controlled trial of a digital educational intervention. BMC Pregnancy and Childbirth, 2021, 21, 565.	0.9	14
8	Prevention of Acquisition of Cytomegalovirus Infection in Pregnancy Through Hygiene-based Behavioral Interventions: A Systematic Review and Gap Analysis. Pediatric Infectious Disease Journal, 2020, 39, 949-954.	1.1	20
9	Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. Journal of Infectious Diseases, 2020, 221, S45-S59.	1.9	25
10	Choice of Study Populations for Vaccines. Journal of Infectious Diseases, 2020, 221, S128-S134.	1.9	5
11	The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Research, 2020, 176, 104732.	1.9	24
12	Mixed cytomegalovirus genotypes in HIV-positive mothers show compartmentalization and distinct patterns of transmission to infants. ELife, 2020, 9, .	2.8	18
13	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clinical Infectious Diseases, 2019, 68, 1420-1426.	2.9	136
14	The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation. Vaccines, 2019, 7, 67.	2.1	12
15	Natural history studies bring universal screening for congenital CMV infection closer. Reviews in Medical Virology, 2019, 29, e2072.	3.9	2
16	Management of HCV periâ€ŧransplant recapitulates management of CMV. Reviews in Medical Virology, 2019, 29, e2091.	3.9	0
17	An explanation for posttransplant lateâ€onset disease associated with CMV prophylaxis. Reviews in Medical Virology, 2019, 29, e2080.	3.9	4
18	Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation. PLoS ONE, 2019, 14, e0210420.	1.1	10

#	Article	IF	CITATIONS
19	Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and metaâ€analysis. Reviews in Medical Virology, 2019, 29, e2034.	3.9	458
20	Age at cytomegalovirus, Epstein Barr virus and varicella zoster virus infection and risk of atopy: the Born in Bradford cohort, UK. Pediatric Allergy and Immunology, 2019, 30, 604-613.	1.1	10
21	Proposed change in an accounting rule in the UK could be good news for vaccinologists. Reviews in Medical Virology, 2019, 29, e2047.	3.9	Ο
22	New vaccines and antiviral drugs for cytomegalovirus. Journal of Clinical Virology, 2019, 116, 58-61.	1.6	22
23	Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients. Journal of Infectious Diseases, 2019, 220, 228-232.	1.9	15
24	Turning cost effectiveness analysis on its head. Reviews in Medical Virology, 2019, 29, e2040.	3.9	0
25	Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation. EBioMedicine, 2019, 50, 45-54.	2.7	12
26	Economic cost of congenital CMV in the UK. Archives of Disease in Childhood, 2019, 104, 559-563.	1.0	43
27	Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6273-6278.	3.3	101
28	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2018, 66, 617-631.	2.9	67
29	Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia. Journal of Infectious Diseases, 2018, 217, 1907-1917.	1.9	61
30	Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient. Reviews in Medical Virology, 2018, 28, e1958.	3.9	18
31	1566. Is Primary CMV Infection Post-transplant Influenced by Circadian Rhythms?. Open Forum Infectious Diseases, 2018, 5, S488-S488.	0.4	Ο
32	Hepatitis E infection in stem cell and solid organ transplantpatients: A cross-sectional study. Journal of Clinical Virology, 2018, 107, 1-5.	1.6	18
33	Cytomegalovirus Infection and HIV. , 2018, , 429-435.		0
34	Diagnosis of Cytomegalovirus Pneumonitis Following Stem Cell Transplantation: Addressing the Yin and Yang of Molecular Methods. Journal of Infectious Diseases, 2017, 215, 1493-1495.	1.9	0
35	Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection in the first two years of life: a cohort study in Bradford, UK. BMC Infectious Diseases, 2017, 17, 220.	1.3	22
36	Screening for potential susceptibility to rubella in an antenatal population: A multivariate analysis. Journal of Medical Virology, 2017, 89, 1532-1538.	2.5	4

#	Article	IF	CITATIONS
37	Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir – Case series and 10 year experience of management in an adult transplant cohort. Journal of Clinical Virology, 2017, 96, 73-79.	1.6	44
38	Characterising variation in five genetic loci of cytomegalovirus during treatment for congenital infection. Journal of Medical Virology, 2017, 89, 502-507.	2.5	8
39	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1 Clinical Infectious Diseases, 2017, 64, 87-91.	2.9	686
40	Herpesviruses and the Hayflick Limit In Vivo. Journal of Infectious Diseases, 2017, 216, 511-513.	1.9	0
41	Why CMV is a candidate for elimination and then eradication. Journal of Virus Eradication, 2016, 2, 131-135.	0.3	8
42	A deletion at CMV UL54 codon 524 without co-existing resistance-associated mutation at UL97 confers resistance to ganciclovir: A case report. Journal of Clinical Virology, 2016, 80, 24-26.	1.6	5
43	Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of human cytomegalovirus genomes. Virus Evolution, 2016, 2, vew017.	2.2	83
44	Zika circumnavigates the globe to go for gold. Reviews in Medical Virology, 2016, 26, 307-308.	3.9	0
45	Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS ONE, 2016, 11, e0163722.	1.1	36
46	Cytomegalovirus Infection and HIV. , 2016, , 1-7.		0
47	Why CMV is a candidate for elimination and then eradication. Journal of Virus Eradication, 2016, 2, 131-5.	0.3	5
48	The kiss of sleeping beauty. Reviews in Medical Virology, 2015, 25, 271-272.	3.9	0
49	The pathogenesis of human cytomegalovirus. Journal of Pathology, 2015, 235, 288-297.	2.1	441
50	Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. Journal of General Virology, 2015, 96, 131-143.	1.3	30
51	Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease. New England Journal of Medicine, 2015, 372, 933-943.	13.9	571
52	Evaluating the feasibility of integrating salivary testing for congenital CMV into the Newborn Hearing Screening Programme in the UK. European Journal of Pediatrics, 2015, 174, 1117-1121.	1.3	21
53	First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F501-F506.	1.4	47
54	Intractable diarrhoea despite immune reconstitution in an HIV positive man. Journal of Clinical Virology, 2015, 69, 219-222.	1.6	1

#	Article	IF	CITATIONS
55	Is Treatment with Bortezomib for Multiple Myeloma or Amyloidosis Associated with Cytomegalovirus Reactivation?. Blood, 2015, 126, 4259-4259.	0.6	1
56	Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2014, 99, F230-F236.	1.4	55
57	Cytomegalovirus. Current Opinion in Infectious Diseases, 2014, 27, 554-559.	1.3	34
58	Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?. Reviews in Medical Virology, 2014, 24, 291-307.	3.9	176
59	Taming the Transplantation Troll by Targeting Terminase. New England Journal of Medicine, 2014, 370, 1844-1846.	13.9	28
60	Encephalitis in an immunocompetent man. Journal of Clinical Virology, 2014, 59, 1-3.	1.6	9
61	Priorities for CMV vaccine development. Vaccine, 2013, 32, 4-10.	1.7	122
62	Surviving another influenza threat. Reviews in Medical Virology, 2013, 23, 267-268.	3.9	1
63	Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine, 2013, 31, B197-B203.	1.7	87
64	Seroprevalence of Cytomegalovirus, Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study. PLoS ONE, 2013, 8, e81881.	1.1	75
65	Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infectious Diseases, The, 2012, 12, 790-798.	4.6	111
66	Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet, The, 2011, 377, 1256-1263.	6.3	352
67	A perspective on antiviral resistance. Journal of Clinical Virology, 2009, 46, 3-8.	1.6	48
68	Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes: the Journal of the IHMF, 2008, 15, 4-12.	0.3	10
69	Antiviral therapy for human cytomegalovirus. , 2007, , 1192-1210.		8
70	Antivirals in the transplant setting. Antiviral Research, 2006, 71, 192-200.	1.9	5
71	Cytomegalovirus. Current Opinion in Infectious Diseases, 2005, 18, 241-245.	1.3	81
72	Genetic content of wild-type human cytomegalovirus. Journal of General Virology, 2004, 85, 1301-1312.	1.3	500

5

#	Article	IF	CITATIONS
73	Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, The, 2004, 363, 2116-2121.	6.3	201
74	Cytomegalovirus infection of the central nervous system. Herpes: the Journal of the IHMF, 2004, 11 Suppl 2, 95A-104A.	0.3	25
75	Therapeutic patents for cytomegalovirus. Expert Opinion on Therapeutic Patents, 2003, 13, 319-327.	2.4	0
76	Two novel spliced genes in human cytomegalovirus. Journal of General Virology, 2003, 84, 1117-1122.	1.3	126
77	Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. Journal of General Virology, 2003, 84, 657-663.	1.3	79
78	The treatment of cytomegalovirus infection. Journal of Antimicrobial Chemotherapy, 2002, 49, 243-253.	1.3	41
79	Tomorrow's Challenges for Herpesvirus Management: Potential Applications of Valacyclovir. Journal of Infectious Diseases, 2002, 186, S131-S137.	1.9	13
80	Human Cytomegalovirus (HCMV) Replication Dynamics in HCMVâ€Naive and â€Experienced Immunocompromised Hosts. Journal of Infectious Diseases, 2002, 185, 1723-1728.	1.9	112
81	Cd8 Cytotoxic Lymphocyte Responses against Cytomegalovirus in Renal Transplant Patients and Healthy Individuals. Clinical Science, 2002, 103, 28P-29P.	0.0	0
82	Molecular diagnosis of cytomegalovirus disease. , 2002, , 467-473.		0
83	Strategies to prevent CMV infection in the neonate. Seminars in Fetal and Neonatal Medicine, 2002, 7, 293-9.	2.8	30
84	Quantity of cytomegalovirus DNA in different leukocyte populations during active infection in vivo and the presence of gB and UL18 transcripts. Journal of Medical Virology, 2001, 64, 283-289.	2.5	38
85	Cytomegalovirus Seropositivity and Human Immunodeficiency Virus Type 1 RNA Levels in Individuals with Hemophilia. Journal of Infectious Diseases, 2000, 181, 1800-1803.	1.9	23
86	Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet, The, 2000, 355, 2032-2036.	6.3	496
87	Interactions between ?-herpesviruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. , 1999, 57, 278-282.		47
88	Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATC). , 1999, 58, 182-187.		60
89	Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. , 1999, 58, 280-285.		17

90 Destruction of smallpox stocks. , 1999, 9, 217-218.

#	Article	IF	CITATIONS
91	The Dynamics of Human Cytomegalovirus Replication in Vivo. Journal of Experimental Medicine, 1999, 190, 177-182.	4.2	244
92	Editorial: HIV: Genetic diversity versus phenotypic selection. , 1998, 8, 1-2.		0
93	Herpes/HIV/hepatitis viruses: biological similarities despite taxonomic differences. , 1998, 8, 117-118.		0
94	Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients. , 1998, 55, 138-146.		6
95	Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. Aids, 1998, 12, 605-611.	1.0	54
96	Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. Aids, 1997, 11, 889-893.	1.0	146
97	Keeping up with progress. , 1997, 7, 1-1.		0
98	How to cross the species-barrier. , 1997, 7, 69-70.		1
99	What virology has taught us. , 1997, 7, 129-129.		0
100	Editorial. , 1996, 6, 185-186.		0
101	Studies on the Etiology of Exanthema Subitum (Roseola Infantum). Reviews in Medical Virology, 1995, 5, 1-6.	3.9	2
102	Viral burden in HIV infection. Nature, 1994, 367, 124-124.	13.7	9
103	Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seropositive donors. Journal of Medical Virology, 1993, 41, 150-158.	2.5	5
104	Clinical Virology in Oral Medicine and Dentistry. Crispian Scully & Lakshman Samaranayake. Pp. 489. Cambridge University Press; 1992. £95.00. ISBN 0 521 40102 X Epidemiology and Infection, 1993, 110, 426-426.	1.0	0
105	The natural history of human immunodeficiency virus infection in a haemophilic cohort. British Journal of Haematology, 1989, 73, 228-234.	1.2	86
106	Comparison of Four Serological Tests for the Detection of Specific Immunoglobulin M in Cord Sera of Infants Congenitally Infected with Cytomegalovirus. Scandinavian Journal of Infectious Diseases, 1987, 19, 303-308.	1.5	23
107	The Demographic Characteristics of Pregnant Women Infected with Cytomegalovirus. International Journal of Epidemiology, 1985, 14, 447-452.	0.9	36
108	ls pregnancy immunosuppressive? Humoral immunity against viruses. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 1168-1175.	1.1	23

#	Article	IF	CITATIONS
109	Herpes Simplex Virus Type 1 and Type 2., 0,, 95-131.		7
110	Hepatitis Viruses. , 0, , 273-320.		7
111	Parainfluenza Viruses. , 0, , 409-439.		3
112	Adenoviruses. , 0, , 463-488.		7
113	Enteroviruses. , 0, , 601-624.		4
114	Alphaviruses. , 0, , 643-668.		4
115	Arenaviruses. , 0, , 733-754.		3
116	Papillomaviruses. , 0, , 807-822.		2
117	Human Parvoviruses. , 0, , 853-867.		1
118	Human Immunodeficiency Viruses. , 0, , 897-938.		6
119	Epstein–Barr Virus. , 0, , 199-221.		6